Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
Status:
Completed
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
Funding Source - FDA OOPD
Pioglitazone is currently used in clinical practice to treat diabetes and this study will
examine the potential use of a low dose of the same drug for the treatment of polycystic
kidney disease. The purpose of this study is to determine whether the diabetes drug
pioglitazone (Actos) is a safe and effective treatment of autosomal dominant polycystic
kidney disease when treated in its early stages. Pioglitazone is approved by the FDA for the
treatment of diabetes. Pre-clinical models of polycystic kidney disease have shown that low
dose treatment with pioglitazone decreases the growth of the cysts. The studies also suggest
that effective pioglitazone dosing for polycystic kidney disease may be lower than that used
to treat diabetes. The purpose of this study is to see if pioglitazone might slow cyst
disease in humans.